YY1-induced PLK1 expression elevates G6PD levels, activating the pentose phosphate pathway and increasing NADPH and glutathione (GSH) production, thereby driving tumor cells’ resistance to paclitaxel and cisplatin [115]. Here, YY1 is linked to neoplasm.